GRITSTONE ONCOLOGY INC's ticker is GRTS and the CUSIP is 39868T105. A total of 67 filers reported holding GRITSTONE ONCOLOGY INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $213,652 | -15.8% | 124,221 | -4.5% | 0.00% | – |
| Q2 2023 | $253,603 | +8.4% | 130,053 | +128.7% | 0.00% | – |
| Q1 2022 | $234,000 | -67.3% | 56,865 | +2.1% | 0.00% | -100.0% |
| Q4 2021 | $716,000 | +27.2% | 55,695 | +6.8% | 0.00% | 0.0% |
| Q3 2021 | $563,000 | +22.7% | 52,129 | +3.8% | 0.00% | 0.0% |
| Q2 2021 | $459,000 | +33.8% | 50,229 | +38.0% | 0.00% | – |
| Q1 2021 | $343,000 | +125.7% | 36,392 | -5.5% | 0.00% | – |
| Q4 2020 | $152,000 | +83.1% | 38,492 | +22.5% | 0.00% | – |
| Q3 2020 | $83,000 | -66.0% | 31,420 | -14.7% | 0.00% | – |
| Q2 2020 | $244,000 | +38.6% | 36,816 | +21.7% | 0.00% | – |
| Q1 2020 | $176,000 | -30.7% | 30,253 | +6.9% | 0.00% | – |
| Q4 2019 | $254,000 | +5.0% | 28,303 | +0.9% | 0.00% | – |
| Q3 2019 | $242,000 | -14.2% | 28,053 | +11.0% | 0.00% | -100.0% |
| Q2 2019 | $282,000 | – | 25,279 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,561,150 | $6,125,178 | 3.26% |
| Redmile Group, LLC | 8,509,126 | $14,635,697 | 0.70% |
| Avidity Partners Management LP | 2,733,800 | $4,702,136 | 0.19% |
| Frazier Life Sciences Management, L.P. | 1,430,878 | $2,461,110 | 0.16% |
| Artia Global Partners LP | 95,170 | $163,692 | 0.07% |
| Worth Venture Partners, LLC | 43,772 | $75,288 | 0.04% |
| SkyOak Wealth, LLC | 60,875 | $104,705 | 0.03% |
| Point72 Asset Management, L.P. | 5,924,867 | $10,190,771 | 0.03% |
| CORNERCAP INVESTMENT COUNSEL INC | 76,811 | $132,115 | 0.02% |
| Houlihan Financial Resource Group, Ltd. | 20,000 | $38 | 0.02% |